IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
about
Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapySome aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversyIDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesPrognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.DNMT3A in haematological malignancies.Clinical and prognostic implications of Roundabout 4 (robo4) in adult patients with acute myeloid leukemia.TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary MyelofibrosisIDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progressionSplicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemiaIsocitrate dehydrogenase mutations in myeloid malignancies.Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes.Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.Clinico-biological significance of suppressor of cytokine signaling 1 expression in acute myeloid leukemia.Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q.The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes.Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution.Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome.Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapyGATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemiaThe prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome
P2860
Q26749870-63FC141E-5C0A-4609-BEE2-3AA54DA70BEEQ27010653-BDBE80D9-9E14-4F8D-AF7F-BF12560126D5Q28066926-3A6C3854-D831-49B3-B364-37F539507ABAQ33769072-DDAB5E80-7CD7-4635-9773-03D40179E0A1Q34463554-B66F6795-A13A-4ED1-AE0B-EB7B624AADDCQ35203340-E935AB83-BA59-41F8-94AA-C2C158481960Q35921904-CD41148B-693F-41B8-8FA1-6F58A2CAB387Q36364763-B5736247-A2AF-454C-8F99-AC2B5C4E4001Q36522731-1886DA4D-67FB-4C3C-BC95-2A2A9A2B1936Q36962514-D9823750-39D0-45C0-964E-9E21BD2282CFQ37625630-DCCD9FB0-17C3-4ECA-B6EA-B4894FBEAFCAQ37654921-3F4F46FB-4D12-49ED-A2A6-CA951C289ACFQ37665288-42BE4A18-7FA1-4B1B-A8EC-D3B65F65C4DFQ38703904-009C07DD-1381-4F8F-A679-FA0F40D4E9A8Q41316658-3EDD8C6D-365E-4A23-9DCB-BF266BF86EA5Q47139135-B5768BD2-9B9C-40A7-BD95-EC1CD2A5818FQ47579728-BC3E1670-4B15-464F-99E5-AD8A8DE36F12Q48595265-E147036C-351F-475E-8509-1C4F521C4A81Q52721521-58315302-EF4E-4AE6-A4A3-5C828E11EDF1Q53058458-9C79E9BD-A24C-4FFA-914A-C3288A92EEE7Q55009819-3B119888-1131-4149-B28E-5185433D606EQ55025720-26DF403D-9D8B-45A3-9DC8-F0BA5F5ECC66Q57795839-76EA53B9-EB6F-499F-880F-D960F94CA1A7Q58781139-D9760166-825F-4468-818F-C0638AA54E3DQ58787070-20DEB007-CFD1-4D61-B3BC-EBCCD8199AE4
P2860
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
IDH mutations are closely asso ...... able during disease evolution.
@en
IDH mutations are closely asso ...... able during disease evolution.
@nl
type
label
IDH mutations are closely asso ...... able during disease evolution.
@en
IDH mutations are closely asso ...... able during disease evolution.
@nl
prefLabel
IDH mutations are closely asso ...... able during disease evolution.
@en
IDH mutations are closely asso ...... able during disease evolution.
@nl
P2093
P2860
P50
P356
P1476
IDH mutations are closely asso ...... able during disease evolution.
@en
P2093
Chi-Fei Huang
Chia-Wen Liu
Chieh-Yu Liu
Chien-Yuan Chen
Fen-Yu Lee
Mei-Hsuan Tseng
Ming-Chih Liu
Shang-Ju Wu
Shang-Yi Huang
P2860
P304
P356
10.1002/AJH.23596
P50
P577
2013-11-20T00:00:00Z